Compare GAIA & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAIA | SCYX |
|---|---|---|
| Founded | 1988 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9M | 37.9M |
| IPO Year | 1999 | 2014 |
| Metric | GAIA | SCYX |
|---|---|---|
| Price | $1.26 | $3.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $3.38 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 95.5K | 66.5K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.18 | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,500,000.00 | $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $977.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.50 | N/A |
| 52 Week Low | $1.16 | $0.66 |
| 52 Week High | $4.48 | $6.09 |
| Indicator | GAIA | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 37.85 |
| Support Level | $1.18 | $0.66 |
| Resistance Level | $1.47 | $4.15 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 8.33 | 31.57 |
Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. The company operates in a single reporting segment. Its revenues is derived from subscription fees for services related to streaming content to the members. Geographically, it derives a majority of its revenue from the United States and also has an International presence.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.